Reported Earlier, FDA Approves Johnson & Johnson's IMAAVY (Nipocalimab-Aahu) As First-Ever Treatment For Warm Autoimmune Hemolytic Anemia, Based On Pivotal Phase 2/3 ENERGY Study

Loading news article.

Reported Earlier, FDA Approves Johnson & Johnson's IMAAVY (Nipocalimab-Aahu) As First-Ever Treatment For Warm Autoimmune Hemolytic Anemia, Based On Pivotal Phase 2/3 ENERGY Study | WAPE

Reported Earlier, FDA Approves Johnson & Johnson's IMAAVY (Nipocalimab-Aahu) As First-Ever Treatment For Warm Autoimmune Hemolytic Anemia, Based On Pivotal Phase 2/3 ENERGY Study

Article summary

Related companies

Comments —